STOCK TITAN

[8-K] Immuneering Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Immuneering Corporation announced its financial results for the quarter ended June 30, 2025 and provided operational updates, and the company furnished the full press release as Exhibit 99.1 to this Current Report. The 8-K itself does not contain the detailed financial figures or operational text; those details are included in the attached press release.

The filing explicitly states that the information is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference into other filings except by specific reference. This document serves as a formal vehicle to make the quarter-end results and operational commentary publicly available, while the substantive metrics and narrative are contained in the exhibit.

Immuneering Corporation ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito aggiornamenti operativi; il comunicato stampa integrale è allegato come Exhibit 99.1 al presente Current Report. L'8-K in sé non riporta i dettagli finanziari o il testo operativo: tali elementi sono inclusi nel comunicato allegato.

La presentazione specifica che le informazioni sono furnished, not filed, ossia fornite ma non formalmente depositate, e pertanto non soggette alle responsabilità previste dalla Section 18 dell'Exchange Act e non vengono incorporate per riferimento in altri documenti, salvo esplicito richiamo. Questo documento funge da mezzo formale per rendere pubblici i risultati di fine trimestre e i commenti operativi, mentre metriche e narrazione sostanziali sono contenute nell'exhibit.

Immuneering Corporation anunció sus resultados financieros del trimestre concluido el 30 de junio de 2025 y proporcionó actualizaciones operativas; el comunicado de prensa íntegro se adjunta como Exhibit 99.1 a este Current Report. El 8-K en sí no incluye las cifras financieras detalladas ni el texto operativo; esos detalles constan en el comunicado adjunto.

La presentación aclara expresamente que la información está furnished, not filed, lo que significa que no está sujeta a las responsabilidades de la Section 18 del Exchange Act y no se incorpora por referencia en otros documentos salvo por referencia específica. Este documento actúa como medio formal para hacer públicos los resultados de cierre de trimestre y los comentarios operativos, mientras que las métricas y la narrativa sustantiva se encuentran en el exhibit.

Immuneering Corporation은 분기 종료일인 2025년 6월 30일자로 분기 실적을 발표하고 운영 현황을 업데이트했으며, 전체 보도자료를 본 Current Report의 Exhibit 99.1로 제출했습니다. 해당 8-K 자체에는 상세한 재무 수치나 운영 관련 텍스트가 포함되어 있지 않으며, 그 내용은 첨부된 보도자료에 기재되어 있습니다.

서류에는 해당 정보가 furnished, not filed로 제출되었음이 명시되어 있어 Exchange Act의 Section 18에 따른 책임의 대상이 아니며, 명시적 참조가 없는 한 다른 제출문서에 참조로 포함되지 않는다고 밝혔습니다. 이 문서는 분기 말 실적과 운영 관련 코멘트를 공개하기 위한 공식적 수단이며, 실질적인 지표와 설명은 exhibit에 포함되어 있습니다.

Immuneering Corporation a annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025 et fourni des mises à jour opérationnelles ; le communiqué de presse intégral est annexé sous la référence Exhibit 99.1 à ce Current Report. Le formulaire 8-K lui‑même ne contient pas les chiffres financiers détaillés ni le texte opérationnel ; ces informations figurent dans le communiqué joint.

Le dépôt précise expressément que l'information est furnished, not filed, ce qui signifie qu'elle n'est pas soumise aux responsabilités prévues par la Section 18 de l'Exchange Act et qu'elle n'est pas incorporée par renvoi dans d'autres dépôts, sauf référence explicite. Ce document sert de moyen formel pour rendre publics les résultats de fin de trimestre et les commentaires opérationnels, tandis que les métriques et le récit substantiel se trouvent dans l'exhibit.

Immuneering Corporation gab die Finanzergebnisse für das Quartal zum 30. Juni 2025 bekannt und meldete betriebliche Aktualisierungen; die vollständige Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigefügt. Der 8-K selbst enthält nicht die detaillierten Finanzzahlen oder den operativen Text; diese Angaben finden sich in der beigefügten Pressemitteilung.

In der Einreichung wird ausdrücklich angegeben, dass die Informationen furnished, not filed sind, was bedeutet, dass sie nicht den Haftungsbestimmungen der Section 18 des Exchange Act unterliegen und nicht durch Verweisung in andere Einreichungen aufgenommen werden, außer durch ausdrückliche Bezugnahme. Dieses Dokument dient als formelles Mittel, die Quartalsabschlussergebnisse und operativen Anmerkungen öffentlich zugänglich zu machen, während die substanziellen Kennzahlen und die Darstellung im Exhibit enthalten sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine earnings announcement furnished without figures; investors must review Exhibit 99.1 for material metrics.

The 8-K notifies the market that Immuneering reported results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. Because the filing does not include revenue, profit, cash balance, or guidance figures, the 8-K alone does not enable assessment of financial performance or trend analysis. The press release exhibit is the primary source for material metrics; the 8-K’s "furnished, not filed" status limits statutory liability but preserves public disclosure obligations.

TL;DR: Disclosure reflects standard compliance practice; the "furnished" designation limits legal exposure while ensuring public access to the release.

This Current Report follows typical disclosure protocol by furnishing a press release and noting it is not "filed" under the Exchange Act. That distinction is important from a governance and disclosure-liability perspective: it provides transparency to the market while limiting the registrant’s Section 18 exposure. The document includes the CEO’s signature block, evidencing authorized corporate attestation of the disclosure process.

Immuneering Corporation ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito aggiornamenti operativi; il comunicato stampa integrale è allegato come Exhibit 99.1 al presente Current Report. L'8-K in sé non riporta i dettagli finanziari o il testo operativo: tali elementi sono inclusi nel comunicato allegato.

La presentazione specifica che le informazioni sono furnished, not filed, ossia fornite ma non formalmente depositate, e pertanto non soggette alle responsabilità previste dalla Section 18 dell'Exchange Act e non vengono incorporate per riferimento in altri documenti, salvo esplicito richiamo. Questo documento funge da mezzo formale per rendere pubblici i risultati di fine trimestre e i commenti operativi, mentre metriche e narrazione sostanziali sono contenute nell'exhibit.

Immuneering Corporation anunció sus resultados financieros del trimestre concluido el 30 de junio de 2025 y proporcionó actualizaciones operativas; el comunicado de prensa íntegro se adjunta como Exhibit 99.1 a este Current Report. El 8-K en sí no incluye las cifras financieras detalladas ni el texto operativo; esos detalles constan en el comunicado adjunto.

La presentación aclara expresamente que la información está furnished, not filed, lo que significa que no está sujeta a las responsabilidades de la Section 18 del Exchange Act y no se incorpora por referencia en otros documentos salvo por referencia específica. Este documento actúa como medio formal para hacer públicos los resultados de cierre de trimestre y los comentarios operativos, mientras que las métricas y la narrativa sustantiva se encuentran en el exhibit.

Immuneering Corporation은 분기 종료일인 2025년 6월 30일자로 분기 실적을 발표하고 운영 현황을 업데이트했으며, 전체 보도자료를 본 Current Report의 Exhibit 99.1로 제출했습니다. 해당 8-K 자체에는 상세한 재무 수치나 운영 관련 텍스트가 포함되어 있지 않으며, 그 내용은 첨부된 보도자료에 기재되어 있습니다.

서류에는 해당 정보가 furnished, not filed로 제출되었음이 명시되어 있어 Exchange Act의 Section 18에 따른 책임의 대상이 아니며, 명시적 참조가 없는 한 다른 제출문서에 참조로 포함되지 않는다고 밝혔습니다. 이 문서는 분기 말 실적과 운영 관련 코멘트를 공개하기 위한 공식적 수단이며, 실질적인 지표와 설명은 exhibit에 포함되어 있습니다.

Immuneering Corporation a annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025 et fourni des mises à jour opérationnelles ; le communiqué de presse intégral est annexé sous la référence Exhibit 99.1 à ce Current Report. Le formulaire 8-K lui‑même ne contient pas les chiffres financiers détaillés ni le texte opérationnel ; ces informations figurent dans le communiqué joint.

Le dépôt précise expressément que l'information est furnished, not filed, ce qui signifie qu'elle n'est pas soumise aux responsabilités prévues par la Section 18 de l'Exchange Act et qu'elle n'est pas incorporée par renvoi dans d'autres dépôts, sauf référence explicite. Ce document sert de moyen formel pour rendre publics les résultats de fin de trimestre et les commentaires opérationnels, tandis que les métriques et le récit substantiel se trouvent dans l'exhibit.

Immuneering Corporation gab die Finanzergebnisse für das Quartal zum 30. Juni 2025 bekannt und meldete betriebliche Aktualisierungen; die vollständige Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigefügt. Der 8-K selbst enthält nicht die detaillierten Finanzzahlen oder den operativen Text; diese Angaben finden sich in der beigefügten Pressemitteilung.

In der Einreichung wird ausdrücklich angegeben, dass die Informationen furnished, not filed sind, was bedeutet, dass sie nicht den Haftungsbestimmungen der Section 18 des Exchange Act unterliegen und nicht durch Verweisung in andere Einreichungen aufgenommen werden, außer durch ausdrückliche Bezugnahme. Dieses Dokument dient als formelles Mittel, die Quartalsabschlussergebnisse und operativen Anmerkungen öffentlich zugänglich zu machen, während die substanziellen Kennzahlen und die Darstellung im Exhibit enthalten sind.

0001790340FALSE00017903402025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
__________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2025
__________________________________
Immuneering Corporation
(Exact name of Registrant as Specified in Its Charter)
__________________________________
Delaware001-4067526-1976972
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
245 Main St.
Second Floor
Cambridge, MA 02142
(Address of principal executive offices) (Zip Code)
(617) 500-8080
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.001 per shareIMRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02. Results of Operations and Financial Condition.
On August 13, 2025, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).
The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:
Exhibit
No.
Description
99.1
Press Release issued on August 13, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNEERING CORPORATION
Date: August 13, 2025
By: /s/ Benjamin J. Zeskind
Name: Benjamin J. Zeskind, Ph.D.
Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)

Immuneering Corp

NASDAQ:IMRX

IMRX Rankings

IMRX Latest News

IMRX Latest SEC Filings

IMRX Stock Data

116.95M
27.21M
24.35%
12.43%
4.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE